06 August 2013 11:57 [Source: ICIS news]
LONDON (ICIS)--Merck Group’s second-quarter net income swung to a €316m ($421m) profit compared with a €63m loss during the same quarter in 2012 on the back of resilient sales and efficiency savings, the company said on Tuesday.
The second-quarter 2012 loss was due in part to a large number of one-off writedowns related to the company's 'Fit for 2018' efficiency savings scheme, according to Merck, but the company’s second-quarter 2013 performance was also an improvement compared with the January-to-March period this year, when the company posted €266m net income.
Sales were steady year on year at €2.74bn, and earnings before interest, taxes, depreciation and amortisation (EBITDA) pre one-time items was up by 11% to €826.4m, the company added.
Performance materials division revenues increased by 1.2% to €431m in spite of a 4.3% impact from currency exchange rate issues.
However, the company predicts an inventory build-up in the industry value chain for liquid crystals – which accounts for over 70% of division sales – meaning that results are for likely to be slightly weaker in the second half of the year.
Consumer health revenues fell by 4.5% year on year to €116m as a result of a slight dip in sales and a 3.5% negative currency impairment. The sales fall was due to weaker demand in Europe, the division’s key market.
Revenues for biopharma division Merck Serono decline by 1.5% to €1.62bn despite a 1.5% increase in sales. Sales growth was driven by a 5.2% expansion in emerging markets and a 13.5% increase in sales across the rest of the world excluding Europe, which declined by 2.7%.
Life sciences division Merck Millipore posted a 2.6% increase in revenues to €666m despite negative currency impacts.
The company predicted that it would be able to meet its earlier guidance for full-year 2013 performance.
“We can confirm our full-year guidance of €3.1bn-3.2bn EBITDA pre [one-time items] despite currency headwinds,” said Karl-Ludwig Kley, chairman of Merck’s executive board.
($1 = €0.75)
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections